Organization
Haider Mahdi
6 clinical trials
Clinical trial
A Phase 2 Open-Label Study to Assess the Antitumor Activity of Neoadjuvant Chemotherapy With or Without HCW9218 in Patients With Metastatic Advanced Stage Ovarian CancerStatus: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
The Efficacy of T-regulatory Cell Depletion With E7777 Combined With Immune Checkpoint Inhibitor, Pembrolizumab, in Recurrent or Metastatic Solid Tumors: Phase I/II StudyStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase l Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Niraparib in Patients With Metastatic or Recurrent Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2029-12-01
Clinical trial
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Patients With Recurrent Platinum-resistant Ovarian Cancer: Phase II StudyStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Post PD1 Exposure: Phase II TrialStatus: Withdrawn, Estimated PCD: 2025-07-01